Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aptamera
Oncology drug makers sign agreement for AGRO100
September 10th, 2003
Aptamera announced that it has signed a product development and license agreement with Archemix Corp. for Aptamera's investigational anticancer drug, AGRO100. As part of this agreement, Archemix, the exclusive holder of rights to the Selex portfolio for aptamer therapeutics, will provide Aptamera with a non-exclusive license to aptamer technology for therapeutic uses of AGRO100 and AGRO100 derivatives. The Selex portfolio consists of more than 160 issued patents covering the selection and use of aptamers. In addition, Archemix will provide Aptamera expertise and know-how in support of these programs. Aptamera remains responsible for the clinical...
Source: Biotech Week (2003-09-10)
|
